Canyon Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 17 Year, 2 Months
- Last Filing with ROC 31 Mar 2022
- Revenue Growth %
- Profit Growth -25.00%
- Ebitda -25.00%
- Net Worth -40.72%
- Total Assets -1.60%
About Canyon Biotech
Canyon Biotech Private Limited (CBPL) is a Private Limited Indian Non-Government Company incorporated in India on 27 December 2007 and has a history of 17 years and two months. Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Musqati Ibrahim and Khalid Masqati serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U01119TG2007PTC056861
- Company No.
056861
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Dec 2007
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Canyon Biotech?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Musqati Ibrahim  | Director | 22-Sep-2020 | Current |
| Khalid Masqati | Director | 22-Sep-2020 | Current |
Financial Performance of Canyon Biotech.
Canyon Biotech Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 25% decrease in profit. The company's net worth observed a substantial decline by a decrease of 40.72%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Canyon Biotech?
In 2018, Canyon Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Masqati Dairy Products LimitedMusqati Ibrahim and Khalid Masqati are mutual person
Sam Bakers Private LimitedMusqati Ibrahim is a mutual person
- Masqati Food Limited
Musqati Ibrahim and Khalid Masqati are mutual person
- Nandini Milks Private Limited
Musqati Ibrahim and Khalid Masqati are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Canyon Biotech?
Unlock and access historical data on people associated with Canyon Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Canyon Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Canyon Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
